Biomarkers Patient Selection Header 

May 5-6, 2015


Implementing Precision Medicine

Understanding Disease Heterogeneity, Status, Trajectory and Treatment Response to Enable Patient Stratification

Jaya Goyal, Ph.D., Director, Translational Sciences, Value Based Medicine, Biogen Idec

Precision Medicine and Biomarker Development at the NCI

Tracy Lively, Ph.D., Program Director, Diagnostics Evaluation, National Cancer Institute, NIH

Prediction of Response to Therapy in Immune Mediated Diseases

Carrie Brodmerkel, Ph.D., Director, Immunology Biomarkers, Johnson and Johnson

Operationally Identifying Pharmacogenetic Variants

Gregory J. Opiteck, Ph.D., Senior Principal Scientist, Merck

Translational and Companion Diagnostic Strategies: A Case Study of Development of PI3K-Beta Inhibitor

Monica Motwani, Ph.D., Director, Precision Medicine & Diagnostics, GlaxoSmithKline


NGS for Biomarker Discovery and Patient Selection

Application of NGS for Biomarker Discovery and Patient Selection

Xiaolan Hu, Ph.D., Head, Clinical Genetics, Bristol Myers Squibb

In-Depth Exome and Transcriptome Analysis for Pediatric Cancer Trials at Phoenix Children's Hospital for Targeted Therapy Development

Nazneen Aziz, Ph.D., Chief Research Officer & Senior Vice President, Phoenix Children’s Hospital

A General Approach to the Discovery and Translation of Multi-Gene Biomarkers in Drug Discovery and Therapy

Wolfgang Sadee, Dr.rer.nat., Professor & Director, College of Medicine Center for Pharmacogenomics, The Ohio State University

Utility of Targeted NGS Panels for Cancer in an Academic Setting

Helen Fernandes, Ph.D., Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College

Clinical Impact of NGS Multi-Gene Panels in Diagnosis and Management of Hereditary Cancer Syndromes

James M. Ford, M.D., Associate Professor, Medicine and Genetics; Director, Stanford Clinical Cancer Genomics Program, Stanford University School of Medicine


Predictive Cancer Biomarkers for Targeted Therapy

Use of Biomarkers for Decision Making in Breast Cancer Therapy

Dennis J. Slamon, M.D., Ph.D., Chief, Hematology & Oncology, The David Geffen School of Medicine, University of California, Los Angeles

The Impact of Multiplexed Genotyping in Directing Cancer Care and a Role for Combining Genotype with Histology for Biomarker Discovery

Darrell R. Borger, Ph.D., Director, Biomarker Laboratory, Massachusetts General Hospital and Harvard Medical School

Developing Biomarkers for Use in Patient Selection in Early Phase Clinical Trials

Ann Kapoun, Ph.D., Vice President, Translational Medicine, OncoMed Pharmaceuticals

Genomic Markers Associated with Pathologic Complete Response and Resistance in Triple Negative Breast Cancer

Christos Hatzis, Ph.D., Assistant Professor, Medicine, and Director, Bioinformatics, Breast Medical Oncology, Yale University School of Medicine

Development of a Homologous Recombination Deficiency (HRD) Companion Diagnostic Test for Selecting High Grade Ovarian Cancer Patients Likely to Respond to the PARP Inhibitor Rucaparib

Mitch Raponi, Ph.D., Senior Director, Molecular Diagnostics, Clovis Oncology


Register Today 

BMC_2014_Final 

Premier Sponsor

 Soma Logic large 

View All Sponsors 

View Media Sponsors